ArticleNutrients2026
Very Low Energy Ketogenic Therapy Effects on Fibrosis-Dependent Metabolic Reprogramming: A Serum NMR Pilot Study.
Article in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND/
objectivesKetogenic diets induce profound metabolic reprogramming; however, their impact on systemic metabolism in patients with hepatic fibrosis remains insufficiently characterized. This study aimed to investigate serum metabolic changes induced by Very Low Energy Ketogenic Therapy (VLEKT) and to assess the influence of hepatic fibrosis development on these metabolic adaptations.
methodsFifty serum samples from 25 obese patients were analyzed using 1D 1H CPMG NMR spectroscopy at baseline (T0) and after 8 weeks of VLEKT (T1). Patients were stratified according to the FIB-E fibrosis index into a low-risk group (LR; FIB-E < 8) and an intermediate-high-risk group (IHR; FIB-E ≥ 8) for hepatic fibrosis onset.
resultsAn integrated approach combining NMR-based metabolomics and pathway enrichment analysis revealed a marked metabolic shift following VLEKT, characterized by increased ketone bodies (including β-hydroxybutyric acid and acetone), together with changes in amino acids and lipid-related signals. Among these, acetone provided a robust and quantifiable NMR signal, consistent with enhanced ketogenesis. Stratified analysis indicated differential metabolic flexibility: LR patients exhibited enhanced modulation of tricarboxylic acid (TCA) cycle-related metabolites, whereas IHR patients showed persistent alterations in aromatic amino acids and lipid signals. Significant correlations between tyrosine and β-alanine with clinical biochemical markers further supported the presence of a fibrosis-dependent metabolic signature.
conclusionsThese findings highlight the potential of circulating metabolites as sensitive and non-invasive indicators of hepatic vulnerability and determinants of metabolic adaptability to VLEKT. Moreover, the study underscores the value of NMR-based metabolomics as an innovative tool for improving the non-invasive assessment of metabolic and hepatic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.